Moderna shares surge 30% in 2026 on raised revenue forecast and cost cuts. Technical breakout suggests continued momentum ...

Moderna shares are volatile Monday after the company provided updates on its business and pipeline at a healthcare conference ...

In the latest trading session, Moderna (MRNA) closed at $33.86, marking a -5.66% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.01%. Meanwhile, the Dow ...

Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a ...

Moderna MRNA shares soared 10.9% in the last trading session to close at $35.66. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the ...

Moderna now anticipates ending 2025 with cash and cash equivalents worth $8.1 billion, up from its previous forecast of ...

Multiple analysts have issued price targets for $MRNA recently. We have seen 10 analysts offer price targets for $MRNA in the last 6 months, with a median target of ...

Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey ...

Investors in Moderna Inc (Symbol: MRNA) saw new options become available today, for the February 2026 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is ...

On January 12, 2026, Moderna reported that it expected unaudited 2025 revenue of about $1.9 billion—slightly above prior guidance—alongside improved projected 2025 GAAP operating expenses of $5.0–$5.2 ...